GeoVax Labs (GOVX) S-1 3 Jan 14 2013 Q3 IPO registration Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	9 Months Ended
	Sep. 30, 2013	Nov. 12, 2013	Jun. 30, 2012
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'GeoVax Labs, Inc.	'	'
Document Type	'S-1	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Common Stock, Shares Outstanding	'	21,716,610	'
Entity Public Float	'	'	$10,176,944
Amendment Flag	'false	'	'
Entity Central Index Key	'0000832489	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Document Period End Date	30-Sep-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'Q3	'	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
Current assets:	'	'	'
Cash and cash equivalents	$1,720,616	$1,035,925	$1,167,980
Grant funds receivable	25,014	266,248	183,515
Prepaid expenses and other current assets	48,262	42,301	66,508
Total current assets	1,793,892	1,344,474	1,418,003
Property and equipment, net of accumulated depreciation and amortization of $474,956 and $429,804 at September 30, 2013 and December 31, 2012, respectively	143,936	102,486	176,206
Other assets:	'	'	'
Licenses, net of accumulated amortization of $236,355 , $228,856 and $208,993 at September 30, 2013, December 31, 2012 and December 31, 2011, respectively	12,500	20,000	39,923
Deposits and other assets	11,010	11,010	11,010
Total other assets	23,510	31,010	50,933
Total assets	1,961,338	1,477,970	1,645,142
Current liabilities:	'	'	'
Accounts payable	85,291	163,788	138,339
Accrued expenses	120,014	33,877	125,869
Amounts payable to Emory University (a related party)	20,225	129,370	677,327
Total current liabilities	225,530	327,035	941,535
Commitments (Note 4)	'	'	'
Stockholders’ equity:	'	'	'
Preferred stock, $0.01 par value, 10,000,000 shares authorized; Series A Convertible Preferred Stock, $1,000 stated value; 788, 788 and 0 shares issued and outstanding at September 30, 2013, December 31, 2012 and December 31, 2011, respectively	312,196	312,196	'
Common stock, $0.001 par value, 75,000,000 shares authorized; 21,666,610, 18,733,277 and 16,442,611 shares issued and outstanding at September 30, 2013, December 31, 2012 and December 31, 2011, respectively	21,667	18,733	16,443
Additional paid-in capital	27,582,316	25,587,148	23,319,166
Deficit accumulated during the development stage	-26,180,371	-24,767,142	-22,632,002
Total stockholders’ equity	1,735,808	1,150,935	703,607
Total liabilities and stockholders’ equity	$1,961,338	$1,477,970	$1,645,142

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
Property and equipment, accumulated depreciation and amortization (in Dollars)	$474,956	$429,804	$356,084
Licenses, accumulated amortization (in Dollars)	$236,355	$228,856	$208,993
Prеfеrrеd stock, par valuе (in Dollars per share)	$0.01	$0.01	$0.01
Prеfеrrеd stock, sharеs authorizеd	10,000,000	10,000,000	10,000,000
Common stock, par value (in Dollars per share)	$0.00	$0.00	'
Common stock, shares authorized	75,000,000	40,000,000	40,000,000
Common stock, shares issued	21,666,610	18,733,277	16,442,611
Common stock, shares outstanding	21,666,610	18,733,277	16,442,611
Series A Convertible Preferred Stock [Member]	'	'	'
Prеfеrrеd stock, sharеs authorizеd	'	2,200	'
Prеfеrrеd stock, statеd valuе (in Dollars per share)	$1,000	$1,000	$1,000
Prеfеrrеd stock, sharеs issuеd	788	788	0
Prеfеrrеd stock, sharеs outstanding	788	788	0

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended		12 Months Ended			138 Months Ended	147 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2012	Sep. 30, 2013
Grant revenue	$1,004,211	$638,000	$2,242,812	$2,197,761	$2,657,327	$4,899,885	$5,185,257	$22,969,019	$25,211,831
Operating expenses:	'	'	'	'	'	'	'	'	'
Research and development	879,104	601,690	2,314,291	2,386,460	3,043,522	4,276,375	4,793,956	28,674,198	30,988,489
General and administrative	316,452	334,166	1,345,179	1,339,300	1,752,765	2,972,555	3,162,134	19,400,424	20,745,603
Total operating expenses	1,195,556	935,856	3,659,470	3,725,760	4,796,287	7,248,930	7,956,090	48,074,622	51,734,092
Loss from operations	-191,345	-297,856	-1,416,658	-1,527,999	-2,138,960	-2,349,045	-2,770,833	-25,105,603	-26,522,261
Other income (expense):	'	'	'	'	'	'	'	'	'
Interest income	1,197	1,077	3,429	2,944	3,820	2,219	23,505	344,130	347,559
Interest expense	'	'	'	'	'	'	'	-5,669	-5,669
Total other income (expense)	1,197	1,077	3,429	2,944	3,820	2,219	23,505	338,461	341,890
Net loss	($190,148)	($296,779)	($1,413,229)	($1,525,055)	($2,135,140)	($2,346,826)	($2,747,328)	($24,767,142)	($26,180,371)
Basic and diluted:	'	'	'	'	'	'	'	'	'
Loss per common share (in Dollars per share)	($0.01)	($0.02)	($0.07)	($0.09)	($0.12)	($0.15)	($0.18)	($2.09)	($2.18)
Weighted average shares outstanding (in Shares)	21,666,610	18,497,886	20,979,675	17,400,665	18,315,669	15,735,541	15,651,308	11,871,955	12,026,183

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (Deficiency) (USD $)	Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Stock Subscription Receivable [Member]	Accumulated Deficit during Development Stage [Member]	Total
Balance at Jun. 26, 2001	'	'	'	'	'	'
Capital contribution at inception (June 27, 2001)	'	'	$10	'	'	$10
Net loss	'	'	'	'	-170,592	-170,592
Balance at Dec. 31, 2001	'	'	10	'	-170,592	-170,582
Net loss	'	'	'	'	-618,137	-618,137
Issuance of common stock	'	2,790	-2,320	'	'	470
Issuance of common stock (in Shares)	'	2,789,954	'	'	'	'
Issuance of common stock for technology license	'	705	148,151	'	'	148,856
Issuance of common stock for technology license (in Shares)	'	704,534	'	'	'	'
Balance at Dec. 31, 2002	'	3,495	145,841	'	-788,729	-639,393
Balance (in Shares) at Dec. 31, 2002	'	3,494,488	'	'	'	'
Net loss	'	'	'	'	-947,804	-947,804
Issuance of common stock	'	1,229	2,458,380	'	'	2,459,609
Issuance of common stock (in Shares)	'	1,229,278	'	'	'	'
Balance at Dec. 31, 2003	'	4,724	2,604,221	'	-1,736,533	872,412
Balance (in Shares) at Dec. 31, 2003	'	4,723,766	'	'	'	'
Net loss	'	'	'	'	-2,351,828	-2,351,828
Issuance of common stock	'	1,483	2,988,436	-2,750,000	'	239,919
Issuance of common stock (in Shares)	'	1,482,605	'	'	'	'
Cash payments received on stock subscription receivable	'	'	'	750,000	'	750,000
Issuance of common stock for technology license	'	49	99,951	'	'	100,000
Issuance of common stock for technology license (in Shares)	'	49,420	'	'	'	'
Balance at Dec. 31, 2004	'	6,256	5,692,608	-2,000,000	-4,088,361	-389,497
Balance (in Shares) at Dec. 31, 2004	'	6,255,791	'	'	'	'
Net loss	'	'	'	'	-1,611,086	-1,611,086
Cash payments received on stock subscription receivable	'	'	'	1,500,000	'	1,500,000
Balance at Dec. 31, 2005	'	6,256	5,692,608	-500,000	-5,699,447	-500,583
Balance (in Shares) at Dec. 31, 2005	'	6,255,791	'	'	'	'
Net loss	'	'	'	'	-584,166	-584,166
Cash payments received on stock subscription receivable	'	'	'	500,000	'	500,000
Conversion of preferred stock to common stock	'	3,551	1,071,565	'	'	1,075,116
Conversion of preferred stock to common stock (in Shares)	'	3,550,851	'	'	'	'
Common stock issued in connection with merger	'	4,360	1,708,489	'	'	1,712,849
Common stock issued in connection with merger (in Shares)	'	4,359,891	'	'	'	'
Issuance of common stock upon option and warrant exercise	'	57	-57	'	'	'
Issuance of common stock upon option and warrant exercise (in Shares)	'	56,825	'	'	'	'
Balance at Dec. 31, 2006	'	14,224	8,472,605	'	-6,283,613	2,203,216
Balance (in Shares) at Dec. 31, 2006	'	14,223,358	'	'	'	'
Net loss	'	'	'	'	-4,241,796	-4,241,796
Issuance of common stock	'	407	3,162,543	'	'	3,162,950
Issuance of common stock (in Shares)	'	406,729	'	'	'	'
Issuance of common stock upon option and warrant exercise	'	2	4,998	'	'	5,000
Issuance of common stock upon option and warrant exercise (in Shares)	'	2,471	'	'	'	'
Stock-based compensation expense	'	'	1,518,496	'	'	1,518,496
Balance at Dec. 31, 2007	'	14,633	13,158,642	'	-10,525,409	2,647,866
Balance (in Shares) at Dec. 31, 2007	'	14,632,558	'	'	'	'
Net loss	'	'	'	'	-3,728,187	-3,728,187
Issuance of common stock	'	306	1,770,785	'	'	1,771,091
Issuance of common stock (in Shares)	'	306,419	'	'	'	'
Issuance of common stock for services	'	10	73,990	'	'	74,000
Issuance of common stock for services (in Shares)	'	10,000	'	'	'	'
Stock-based compensation expense	'	'	1,945,049	'	'	1,945,049
Balance at Dec. 31, 2008	'	14,949	16,948,466	'	-14,253,596	2,709,819
Balance (in Shares) at Dec. 31, 2008	'	14,948,977	'	'	'	'
Net loss	'	'	'	'	-3,284,252	-3,284,252
Issuance of common stock	'	216	1,519,784	'	'	1,520,000
Issuance of common stock (in Shares)	'	216,261	'	'	'	'
Issuance of common stock for services	'	5	31,495	'	'	31,500
Issuance of common stock for services (in Shares)	'	4,500	'	'	'	'
Issuance of common stock upon option and warrant exercise	'	463	1,499,537	'	'	1,500,000
Issuance of common stock upon option and warrant exercise (in Shares)	'	462,826	'	'	'	'
Stock-based compensation expense	'	'	1,267,165	'	'	1,267,165
Balance at Dec. 31, 2009	'	15,633	21,266,447	'	-17,537,848	3,744,232
Balance (in Shares) at Dec. 31, 2009	'	15,632,564	'	'	'	'
Net loss	'	'	'	'	-2,747,328	-2,747,328
Issuance of common stock	'	12	89,988	'	'	90,000
Issuance of common stock (in Shares)	'	12,000	'	'	'	'
Issuance of common stock for services	'	10	53,803	'	'	53,813
Issuance of common stock for services (in Shares)	'	10,500	'	'	'	10,500
Stock-based compensation expense	'	'	696,719	'	'	696,719
Fractional share cash payout upon reverse split	'	'	-1,210	'	'	-1,210
Fractional share cash payout upon reverse split (in Shares)	'	-218	'	'	'	'
Balance at Dec. 31, 2010	'	15,655	22,105,747	'	-20,285,176	1,836,226
Balance (in Shares) at Dec. 31, 2010	'	15,654,846	'	'	'	'
Net loss	'	'	'	'	-2,346,826	-2,346,826
Issuance of common stock	'	659	440,551	'	'	441,210
Issuance of common stock (in Shares)	'	658,520	'	'	'	'
Issuance of common stock for services	'	129	149,871	'	'	150,000
Issuance of common stock for services (in Shares)	'	129,245	'	'	'	129,245
Cash payments received on stock subscription receivable	'	'	'	'	'	404,410
Stock-based compensation expense	'	'	622,997	'	'	622,997
Balance at Dec. 31, 2011	'	16,443	23,319,166	'	-22,632,002	703,607
Balance (in Shares) at Dec. 31, 2011	'	16,442,611	'	'	'	'
Net loss	'	'	'	'	-2,135,140	-2,135,140
Issuance of common stock	'	408	272,952	'	'	273,360
Issuance of common stock (in Shares)	'	407,999	'	'	'	'
Sale of convertible preferred stock and warrants for cash	871,614	'	1,127,418	'	'	1,999,032
Sale of convertible preferred stock and warrants for cash (in Shares)	2,200	'	'	'	'	'
Issuance of common stock for services (in Shares)	'	'	'	'	'	0
Cash payments received on stock subscription receivable	'	'	'	'	'	310,160
Conversion of preferred stock to common stock	-559,418	1,882	557,536	'	'	'
Conversion of preferred stock to common stock (in Shares)	-1,412	1,882,667	'	'	'	'
Issuance of common stock upon option and warrant exercise (in Shares)	'	'	'	'	'	0
Stock-based compensation expense	'	'	310,076	'	'	310,076
Balance at Dec. 31, 2012	$312,196	$18,733	$25,587,148	'	($24,767,142)	$1,150,935
Balance (in Shares) at Dec. 31, 2012	788	18,733,277	'	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended				12 Months Ended				138 Months Ended	147 Months Ended
	Sep. 30, 2013		Sep. 30, 2012		Dec. 31, 2012		Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2012	Sep. 30, 2013
Net loss	($1,413,229)		($1,525,055)		($2,135,140)		($2,346,826)	($2,747,328)	($24,767,142)	($26,180,371)
Depreciation and amortization	52,652		70,232		93,643		109,017	119,773	659,280	711,932
Accretion of preferred stock redemption value	'		'		'		'	'	346,673	346,673
Stock-based compensation expense	116,600		247,318		310,076		772,997	750,532	6,669,815	6,634,289
Investor warrant modification expense	238,169		'		'		152,126	'	'	390,295
Grant funds receivable	241,234		-65,020		-82,733		290,760	-153,954	-266,248	-25,014
Prepaid expenses and other current assets	-5,961		-17,204		-12,593		19,122	-4,215	-42,301	-48,262
Deferred offering costs	'		'		'		430,402	-430,402	'	'
Deposits and other assets	'		'		'		980	-11,010	-11,010	-11,010
Accounts payable and accrued expenses	-101,505		-603,624		-614,500		419,927	39,033	415,825	314,320
Total adjustments	541,189		-368,298		-306,107		2,043,205	309,757	7,772,034	8,313,223
Net cash used in operating activities	-872,040		-1,893,353		-2,441,247		-303,621	-2,437,571	-16,995,108	-17,867,148
Purchase of property and equipment	-86,602		'		'		-11,896	-4,706	-538,490	-625,092
Proceeds from sale of property and equipment	'		'		'		'	5,580	5,580	5,580
Net cash used in investing activities	-86,602		'		'		-11,896	874	-532,910	-619,512
Net proceeds from sale of common stock	1,643,333		310,160		310,160		404,410	'	15,836,468	17,479,801
Net proceeds from sale of preferred stock	'		1,999,032		1,999,032		'	'	2,727,475	2,727,475
Net cash provided by financing activities	1,643,333	[1]	2,309,192	[1]	2,309,192	[1]	404,410	'	18,563,943	20,207,276	[1]
Net increase in cash and cash equivalents	684,691		415,839		-132,055		88,893	-2,436,697	1,035,925	1,720,616
Cash and cash equivalents at beginning of period	1,035,925		1,167,980		1,167,980		1,079,087	3,515,784	'	'
Cash and cash equivalents at end of period	1,720,616		1,583,819		1,035,925		1,167,980	1,079,087	1,035,925	1,720,616
Interest paid	'		'		'		'	'	$5,669	$5,669
[1]	Supplemental disclosure of non-cash investing and financing activities: In connection with the Merger discussed in Note 5, all of the then outstanding shares of the Company's mandatory redeemable convertible preferred stock were converted into shares of common stock as of September 28, 2006. As discussed in Note 6, during 2012, an aggregate of 1,412 shares of the Company's outstanding Series A Convertible Preferred Stock were converted into 1,882,667 shares of common stock.

Note_1_Description_of_Company_

Note 1 - Description of Company and Basis of Presentation	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	'
	1.            Description of Company and Basis of Presentation
	GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a biotechnology company developing vaccines for the prevention and treatment of Human Immunodeficiency Virus (“HIV”) infections. HIV infections result in Acquired Immunodeficiency Syndrome (“AIDS”). We have exclusively licensed from Emory University (“Emory”) vaccine technology which was developed in collaboration with the National Institutes of Health (“NIH”) and the Centers for Disease Control and Prevention (“CDC”). GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in Smyrna, Georgia (metropolitan Atlanta area).
	Our most advanced vaccines under development address the clade B subtype of the HIV virus that is most prevalent in the United States and the developed world. Our vaccines are being evaluated to determine their potential to (a) prevent HIV infection and (b) to serve as a therapy for individuals who are already infected with HIV. These vaccines are currently being evaluated in human clinical trials.
	GeoVax is devoting all of its present efforts to research and development and is a development stage enterprise as defined by Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 915, “Development Stage Entities”. We have funded our activities to date almost exclusively from equity financings and government grants, and we will continue to require substantial funds to continue these activities. We anticipate that our existing cash resources, combined with the proceeds from the NIH grants discussed in Note 7, will be sufficient to fund our planned activities into the second quarter of 2014. In order to meet our future operating cash flow requirements, we intend to conduct additional offerings of our equity securities, debt or convertible debt instruments. We are also seeking additional funding for our vaccine development programs through government grants and clinical trial support.
	The accompanying financial statements at September 30, 2013 and for the three and nine month periods ended September 30, 2013 and 2012 are unaudited, but include all adjustments, consisting of normal recurring entries, which we believe to be necessary for a fair presentation of the dates and periods presented. Interim results are not necessarily indicative of results for a full year. The financial statements should be read in conjunction with our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2012. We expect our operating results to fluctuate for the foreseeable future; therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods.
	We disclosed in Note 2 to our financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2012 those accounting policies that we consider significant in determining our results of operations and financial position. There have been no material changes to, or in the application of, the accounting policies previously identified and described in the Form 10-K.

Note_2_Recent_Accounting_Prono

Note 2 - Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block [Abstract]	'
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	'
	2.            Recent Accounting Pronouncements
	There have been no recent accounting pronouncements or changes in accounting pronouncements during the nine months ended September 30, 2013, as compared to the recent accounting pronouncements described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2012, which we expect to have a material impact on our financial statements.

Note_3_Basic_and_Diluted_Loss_

Note 3 - Basic and Diluted Loss Per Common Share	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	3.            Basic and Diluted Loss Per Common Share
	Basic net loss per share is computed using the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares and potentially dilutive common share equivalents outstanding during the period. Potentially dilutive common share equivalents consist of convertible preferred stock, stock options and stock purchase warrants. Common share equivalents which potentially could dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, as the effect would be anti-dilutive, totaled approximately 10.3 million and 13.2 million shares at September 30, 2013 and 2012, respectively.

Note_4_Commitments

Note 4 - Commitments	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	4.            Commitments
	Lease Agreement
	We lease approximately 8,400 square feet of office and laboratory space located in Smyrna, Georgia (metropolitan Atlanta). As of September 30, 2013, our future minimum lease payments pursuant to the 62 month operating lease total $31,760 for the remainder of 2013 and $128,920 in 2014.
	Other Commitments
	In the normal course of business, we may enter into various firm purchase commitments related to production and testing of our vaccine material, conduct of our clinical trials, and other research-related activities. As of September 30, 2013, we had approximately $59,985 of unrecorded outstanding purchase commitments to our vendors and subcontractors, all of which we expect will be due in 2013.

Note_5_Stockholders_Equity

Note 5 - Stockholders' Equity	9 Months Ended						12 Months Ended
	Sep. 30, 2013						Dec. 31, 2012
Stockholders' Equity Note [Abstract]	'						'
Stockholders' Equity Note Disclosure [Text Block]	'						'
	5.            Stockholders’ Equity						6.           Stockholders’ Equity
	Increase in Authorized Shares of Common Stock						Series A Convertible Preferred Stock
	At our annual meeting of stockholders held on June 10, 2013, our stockholders approved an amendment to our certificate of incorporation to increase our authorized shares of common stock from 40,000,000 shares to 75,000,000 shares. The amendment to our certificate of incorporation was filed with the Delaware Secretary of State on August 1, 2013. In addition to the 21,666,610 shares of common stock outstanding at September 30, 2013, we have reserved the following shares of our common stock for future issuance:						Our Certificate of Incorporation authorizes us to issue up to 10,000,000 shares of preferred stock, $.01 par value.  In March 2012, we established from the authorized preferred stock a series of preferred stock, consisting of 2,200 shares of Series A Convertible Preferred Stock, $1,000 stated value (“Series A Preferred Shares”) and entered into a Securities Purchase Agreement (“SPA”) whereby we issued to three institutional investors (“Purchasers”) the Series A Preferred Shares for gross proceeds of $2.2 million.  Net proceeds to the Company from this transaction, after deduction of placement agent fees and other expenses, were approximately $2.0 million.
	Common Stock Purchase Warrants		8,292,226				The Series A Preferred Shares may be converted at any time at the option of the Purchasers into shares of our common stock at a conversion price of $0.75 per share (“Conversion Price”), for an initial aggregate total of 2,933,333 shares of our common stock (“Conversion Shares”).  The Series A Preferred Shares have a liquidation preference equal to the initial purchase price, have no voting rights, and are not entitled to a dividend.  Through December 31, 2012, a total of 1,412 Series A Preferred Shares have been converted into 1,882,667 shares of our common stock.  As of December 31, 2012, there were 788 shares of Series A Preferred Shares outstanding, convertible into 1,050,667 shares of our common stock.
	Equity Incentive Plans		1,197,529
	Series A Convertible Preferred Stock		1,050,667				Pursuant to the terms of the SPA, we issued to each Purchaser Series A, B and C Warrants (collectively, the “Warrants”), each to purchase up to a number of shares of our common stock equal to 100% of the Conversion Shares underlying the Series A Preferred Shares (up to 2,933,333 shares in the aggregate for each of the three series of warrants, or 8,799,999 shares in total) (“Warrant Shares”).  The Series A Warrants have an exercise price of $1.00 per share, are exercisable immediately, and expire on March 21, 2017.  The Series B Warrants have an exercise price of $0.75 per share, are exercisable immediately, and expire on March 21, 2013. The Series C Warrants have an exercise price of $1.00 per share and expire on March 21, 2017, but only vest and become exercisable upon, and in proportion to, the exercise of the one-year Series B Warrants.  The Warrants contain anti-dilution provisions, which may, under certain circumstances, reduce the exercise price (but have no effect on the number of shares subject to the Warrants) if we sell or grant options to purchase, including rights to reprice, our common stock or common stock equivalents at a price lower than the exercise price of the Warrants, or if we announce plans to do so.
	Total		10,540,422
							In connection with the sale of the Series A Preferred Shares, we entered into a Registration Rights Agreement (“RRA”) with the Purchasers, pursuant to which we filed a registration statement with the Securities and Exchange Commission (“SEC”) on April 3, 2012 covering resale of the Conversion Shares and the Warrant Shares.   It was declared effective by the SEC on April 13, 2012
	Common Stock Transactions
							Accounting Treatment and Allocation of Proceeds.  We first assessed the Series A Preferred Shares under ASC Topic 480, “Distinguishing Liabilities from Equity” (“ASC 480”) and determined such preferred stock not to be a liability under ASC 480.  We next assessed the preferred stock under ASC Topic 815. “Derivatives and Hedging” (“ASC 815”).  The preferred stock contains an embedded feature allowing an optional conversion by the holder into common stock which meets the definition of a derivative.  However, we believe that the preferred stock is an “equity host” (as described by ASC 815) for purposes of assessing the embedded derivative for potential bifurcation and determined that the optional conversion feature is clearly and closely associated to the preferred stock host; we therefore determined that the embedded derivative does not require bifurcation and separate recognition under ASC 815.  We then assessed the preferred stock under ASC Topic 470, “Debt” (“ASC 470”), and determined there to be a beneficial conversion feature (“BCF”) requiring recognition at its intrinsic value.  Since the conversion option of the preferred stock was immediately exercisable, the amount allocated to the BCF was immediately accreted to preferred dividends, resulting in an increase in the carrying value of the preferred stock.  We also assessed the warrants issued in connection with the financing under ASC 815 and determined that they did not initially meet the definition of a derivative, but will require evaluation on an on-going basis.  As of December 31, 2012, we determined that the warrants still did not meet the definition of a derivative.
	During January and May 2013, we issued an aggregate of 1,766,667 shares and 1,166,666 shares, respectively, of our common stock pursuant to the exercise of Series B Warrants, resulting in total proceeds of $1,060,000 and $583,333, respectively (see ”Stock Purchase Warrants” below).
							The following is a summary of the allocation of the net proceeds from the preferred stock financing, and reconciliation to the carrying value at December 31, 2012:
	Stock Options
							Net proceeds after transaction costs	$	1,999,032
	The Company maintains a stock option plan that provides the Board of Directors broad discretion in creating equity incentives for employees, officers, directors and consultants. The following table presents a summary of stock option transactions during the nine months ended September 30, 2013:						Less:       Fair value of warrants (recorded to Additional Paid-in Capital)		(1,127,418	)
							Beneficial conversion feature (recorded to Additional Paid-in Capital)		(762,667	)
		Number of Shares			Weighted Average		Net proceeds allocated to preferred stock		108,947
					Exercise Price		Accretion of beneficial conversion feature (deemed dividend)		762,667
	Outstanding at December 31, 2012		1,069,141		$	4.5	Initial carrying value of preferred stock		871,614
	Granted		--			--	Conversions to common stock		(559,418	)
	Exercised		--			--	Carrying value of preferred stock at December 31, 2012	$	312,196
	Forfeited or expired		(78,429	)		4.86
	Outstanding at September 30, 2013		990,712		$	4.47	Common Stock Transactions
	Exercisable at September 30, 2013		679,036		$	6.14
							In February 2010, we issued 12,000 shares of our common stock in settlement of an obligation accrued at December 31, 2009 in the amount of $90,000.
	During the three month and nine month periods ended September 30, 2013, we recorded share-based compensation expense related to stock options of $33,348 and $116,600, as compared to $84,742 and $247,318 for the three month and nine month periods ended September 30, 2012, respectively. Share-based compensation expense is recognized on a straight-line basis over the requisite service period for the award and is allocated to research and development expense or general and administrative expense based upon the related employee classification. As of September 30, 2013, there was $135,418 of unrecognized compensation expense related to stock options, which is expected to be recognized over a weighted average period of 1.7 years.
							During December 2011, we sold an aggregate of 658,520 shares of our common stock to a group of individual accredited investors (including members of our board of directors and management --see Note 9) for an aggregate purchase price of $441,210, $36,800 of which was received in January 2012 and is therefore reflected as a receivable (Other Current Asset) in the accompanying Consolidated Balance Sheet as of December 31, 2011.  We also issued to the investors warrants to purchase an aggregate of 987,783 shares of common stock at a price of $1.00 per share, which expire in December 2016.
	Stock Purchase Warrants
							During January 2012, we sold an aggregate of 407,999 shares of our common stock to a group of individual accredited investors (including members of our board of directors and management --see Note 9) for an aggregate purchase price of $273,360.  We also issued to the investors warrants to purchase an aggregate of 612,001 shares of common stock at a price of $1.00 per share, which expire in January 2017.
	We have issued stock purchase warrants in connection with financing transactions and also in exchange for services from consultants and others. The following table presents a summary of stock purchase warrant transactions during the nine months ended September 30, 2013:
							From time to time, we issue shares of our common stock to consultants or others in exchange for services.  During 2012, 2011 and 2010 we issued -0-, 129,245, and 10,500 shares, respectively, for such services; and we recorded general and administrative expense of $-0-, $150,000, and $53,813 during each respective period related to these issuances.
		Number of Shares			Weighted Average
					Exercise Price		Stock Options
	Outstanding at December 31, 2012		11,225,559		$	2.06
	Issued		--			--	In 2006, we adopted the GeoVax Labs, Inc. 2006 Equity Incentive Plan (the “Stock Option Plan”) for the granting of qualified incentive stock options (“ISO’s”), nonqualified stock options, restricted stock awards or restricted stock bonuses to employees, officers, directors, consultants and advisors of the Company.  The exercise price for any option granted may not be less than fair value (110% of fair value for ISO’s granted to certain employees).  Options granted under the Stock Option Plan have a maximum ten-year term and generally vest over three years.  The Company has reserved 1,200,000 shares of its common stock for issuance under the Stock Option Plan.
	Exercised		(2,933,333	)		0.56
	Forfeited or expired		--			--	A summary of activity under the Stock Option Plan as of December 31, 2012, and changes during the year then ended is presented below:
	Outstanding at September 30, 2013		8,292,226		$	2.53
	Exercisable at September 30, 2013		8,292,226		$	2.53		Number			Weighted-			Weighted-			Aggregate
								of Shares			Average			Average			Intrinsic
	Effective January 17, 2013, we reduced the exercise price of our then-outstanding Series B Common Stock Purchase Warrants from $0.75 to $0.60 per share. In consideration for the reduction of the exercise price, the holders of the Series B Warrants immediately exercised 1,766,667 of the Series B Warrants for cash, resulting in total proceeds to the Company of $1,060,000. We also extended the expiration date of the unexercised Series B Warrants (1,166,667 shares in the aggregate) from March 21, 2013 to May 21, 2013. We recorded general and administrative expense of $218,551 associated with these warrant modifications, all of which was recognized during the three month period ended March 31, 2013.										Exercise			Remaining			Value
											Price			Contractual
	Effective May 14, 2013, we reduced the exercise price of the remaining Series B Common Stock Purchase Warrants from $0.60 to $0.50 per share. In consideration for the reduction of the exercise price, the holders of the Series B Warrants immediately exercised all 1,166,666 of the remaining Series B Warrants for cash, resulting in total proceeds to the Company of $583,333. We recorded general and administrative expense of $19,617 associated with this warrant modification, all of which was recognized during the three month period ended June 30, 2013.													Term (yrs)
							Outstanding at December 31, 2011		928,242		$	5.43
							Granted		238,500			0.7
							Exercised		-			-
							Forfeited or expired		(97,601	)		4.02
							Outstanding at December 31, 2012		1,069,141		$	4.5			6.2		$	-0-
							Exercisable at December 31, 2012		698,995		$	6.38			4.6		$	-0-
							Additional information concerning our stock options for the years ended December 31, 2012, 2011 and 2010 is as follows:
								2012			2011			2010
							Weighted average fair value of options granted during the period	$	0.59		$	0.79		$	2.95
							Intrinsic value of options exercised during the period		-			-			-
							Total fair value of options vested during the period		319,920			540,339			499,557
							We use the Black-Scholes model for determining the grant date fair value of our stock option grants.  This model utilizes certain information, such as the interest rate on a risk-free security with a term generally equivalent to the expected life of the option being valued and requires certain other assumptions, such as the expected amount of time an option will be outstanding until it is exercised or expired, to calculate the fair value of stock options granted.  The significant assumptions we used in our fair value calculations were as follows:
								2012			2011			2010
							Weighted average risk-free interest rates		1.1	%		1.4	%		2.6	%
							Expected dividend yield		0	%		0	%		0	%
							Expected life of option (yrs)	6.7			7			6.7
							Expected volatility		105.2	%		111.2	%		112.9	%
							Stock-based compensation expense related to the Stock Option Plan was $310,076, $463,752, and $575,662 during the years ended December 31, 2012, 2011 and 2010, respectively.  Stock option expense is allocated to research and development expense or to general and administrative expense based on the related employee classifications and corresponds to the allocation of employee salaries.  For the three years ended December 31, 2012, stock option expense was allocated as follows:
								2012			2011			2010
							General and administrative expense	$	231,936		$	284,352		$	369,161
						Research and development expense		78,140			179,400			206,501
						Total stock option expense	$	310,076		$	463,752		$	575,662
						As of December 31, 2012, there was $271,901 of unrecognized compensation expense related to stock-based compensation arrangements.  The unrecognized compensation expense is expected to be recognized over a weighted average remaining period of 2.1 years.
						Stock Purchase Warrants
						We have issued stock purchase warrants in connection with financing transactions and also in exchange for services from consultants and others.  The following table presents a summary of stock purchase warrant transactions during the year ended December 31, 2012:
							Number of Shares			Weighted Average
										Exercise Price
						Outstanding at December 31, 2011		1,870,559		$	7.96
						Issued – Series A Warrants (1)		2,933,333			1
						Issued – Series B Warrants (1)		2,933,333			0.75
						Issued – Series C Warrants (1)		2,933,333			1
						Issued – Other Warrants (2)		612,001			1
						Exercised		--			--
						Forfeited or expired		(57,000	)		7
						Outstanding at December 31, 2012		11,225,559		$	2.06
						Exercisable at December 31, 2012		8,290,376		$	2.44
						(1)      See discussion under “Series A Convertible Preferred Stock” above.
						(2)      See discussion under “Common Stock Transactions” above.
						For stock purchase warrants issued to consultants or others in exchange for services, we record the related expense over the service period, or upon the date, that the service was rendered.  Expense associated with such compensatory warrants was $-0-, $7,119, and $121,057 during the years ended December 31, 2012, 2011 and 2010, respectively All such expense was allocated to general and administrative expense.  As of December 31, 2012, there was no unrecognized compensation expense related to compensatory warrants. .  In addition to compensatory warrant expense, during 2011 we recorded $152,126 of general and administrative expense associated with the extension of certain investor warrants which were due to expire in 2011 to 2013.  In January 2013, certain modifications were made to the terms of the Class B Warrants in exchange for the exercise of a portion of those warrants (see Note 11).

Note_6_Income_Taxes

Note 6 - Income Taxes	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Income Tax Disclosure [Text Block]	'	'
	6.            Income Taxes	8.           Income Taxes
	Because of our historically significant net operating losses, we have not paid income taxes since inception. We maintain deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets are comprised primarily of net operating loss carryforwards and also include amounts relating to nonqualified stock options and research and development credits. The net deferred tax asset has been fully offset by a valuation allowance because of the uncertainty of our future profitability and our ability to utilize the deferred tax assets. Utilization of operating losses and credits may be subject to substantial annual limitations due to ownership change provisions of Section 382 of the Internal Revenue Code. The annual limitation may result in the expiration of net operating losses and credits before utilization.	At December 31, 2012, we have a consolidated federal net operating loss (“NOL”) carryforward of approximately $69.8 million, available to offset against future taxable income which expires in varying amounts in 2013 through 2032.  Additionally, we have approximately $764,000 in research and development (“R&D”) tax credits that expire in 2022 through 2031 unless utilized earlier.  No income taxes have been paid to date.
		As a result of the Merger discussed in Note 5, our NOL carryforward increased substantially due to the addition of historical NOL carryforwards for Dauphin Technology, Inc.  However, Section 382 of the Internal Revenue Code contains provisions that may limit our utilization of NOL and R&D tax credit carryforwards in any given year as a result of significant changes in ownership interests that have occurred in past periods or may occur in future periods.
		Deferred income taxes reflect the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Significant components of our deferred tax assets and liabilities included the following at December 31, 2012 and 2011:
			2012			2011
		Deferred tax assets:
		Net operating loss carryforward	$	24,429,472		$	24,872,082
		Research and development tax credit carryforward		763,965			763,690
		Stock-based compensation expense		2,097,194			1,991,769
		Total deferred tax assets		27,290,631			27,627,541
		Deferred tax liabilities
		Depreciation		(16,125	)		(36,311	)
		Total deferred tax liabilities		(16,125	)		(36,311	)
		Net deferred tax assets		27,274,506			27,591,230
		Valuation allowance		(27,274,506	)		(27,591,230	)
			$	-		$	-
		We have established a full valuation allowance equal to the amount of our net deferred tax assets due to uncertainties with respect to our ability to generate sufficient taxable income to realize these assets in the future. A reconciliation of the income tax benefit on losses at the U.S. federal statutory rate to the reported income tax expense is as follows:
			2012			2011			2010
		U.S. federal statutory rate applied to pretax loss	$	(725,948	)	$	(797,921	)	$	(934,092	)
		Permanent differences		2,674			4,216			(77,200	)
		Research and development credits		-			32,675			59,959
		Change in valuation allowance		723,274			761,030			951,333
		Reported income tax expense	$	-		$	-		$	-

Note_7_NIH_Grant_Funding

Note 7 - NIH Grant Funding	9 Months Ended
	Sep. 30, 2013
Grant Funding [Abstract]	'
Grant Funding [Text Block]	'
	7.            NIH Grant Funding
	In September 2007, the NIH awarded us an Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant to support our HIV/AIDS vaccine program. We are utilizing this funding to further our HIV/AIDS vaccine development, optimization and production. The aggregate award (including subsequent amendments) totaled $20.4 million, and there is approximately $773,000 remaining and available for use as of September 30, 2013.
	In September 2012, the NIH awarded us an additional grant of $1.9 million to support development of versions of our HIV/AIDS vaccines to address the clade C subtype of the HIV virus prevalent in the developing world. All funding pursuant to this grant has been utilized as of September 30, 2013.
	In July 2013, the NIH awarded us a Small Business Innovative Research (SBIR) grant entitled “Enhancing Protective Antibody Responses for a GM-CSF Adjuvanted HIV Vaccine.” The grant award of approximately $277,000 is for the first year of a two year project period beginning August 1, 2013, and there is approximately $249,000 remaining and available for use as of September 30, 2013.
	We record revenue associated with these grants as the related costs and expenses are incurred and such revenue is reported as a separate line item in our statements of operations.

Note_8_Related_Party_Transacti

Note 8 - Related Party Transactions	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Related Party Transactions [Abstract]	'	'
Related Party Transactions Disclosure [Text Block]	'	'
	8.            Related Party Transactions	9.           Related Party Transactions
	We are obligated to reimburse Emory University (a significant stockholder of the Company) for certain prior and ongoing costs in connection with the filing, prosecution and maintenance of patent applications subject to our technology license agreement from Emory. During the nine month period ended September 30, 2013, we recorded $24,115 of general and administrative expense associated with these patent cost reimbursements to Emory.	We are obligated to reimburse Emory University (a significant stockholder of the Company) for ongoing costs in connection with the filing, prosecution and maintenance of patent applications subject to a license agreement for technology associated with the vaccines we are developing.  The expense associated with these ongoing patent cost reimbursements to Emory amounted to $89,885, $249,907, and $193,674 for the years ended December 31, 2012, 2011, and 2010, respectively.
	We have entered into a research agreement with Emory for the purpose of conducting research and development activities associated with our IPCAVD grant from the NIH (see Note 7). During the nine month period ended September 30, 2013, we recorded $252,478 of research and development expense associated with this contract. All amounts paid to Emory under this agreement are reimbursable to us pursuant to the NIH grant.	In connection with our IPCAVD grant from the NIH (see Note 3), we have entered into two subcontracts with Emory for the purpose of conducting research and development activities related to the grant.  During 2012, 2011, and 2010, we recorded $552,403, $1,172,758, and $1,391,203, respectively, of expense associated with these subcontracts.  All amounts paid to Emory under these subcontracts are reimbursable to us pursuant to the NIH grant.
		In March 2008, we entered into a consulting agreement with Donald Hildebrand, a former member of our Board of Directors and our former President & Chief Executive Officer, pursuant to which Mr. Hildebrand has provided business and technical advisory services to the Company.  The term of the consulting agreement, as amended, began on April 1, 2008 and ended on December 31, 2012.  During 2012, 2011, and 2010, we recorded $24,000, $24,000, and $57,600, respectively, of expense associated with the consulting agreement.
		In December 2011 and January 2012, members of our management and Board of Directors participated in the private placement offering of our common stock and warrants (see Note 6), whereby they purchased an aggregate of 380,954 shares of our common stock for a total purchase price of $255,239 and received five-year warrants to purchase an additional 571,432 shares of our common stock exercisable at $1.00 per share.

Note_1_Nature_of_Business

Note 1 - Nature of Business	12 Months Ended
	Dec. 31, 2012
Disclosure Text Block [Abstract]	'
Nature of Operations [Text Block]	'
	1.           Nature of Business
	GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a biotechnology company developing vaccines that prevent and fight Human Immunodeficiency Virus (“HIV”) infections.  HIV infections result in Acquired Immunodeficiency Syndrome (“AIDS”).  We have exclusively licensed from Emory University (“Emory”) vaccine technology which was developed in collaboration with the National Institutes of Health (“NIH”) and the Centers for Disease Control and Prevention (“CDC”).  GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in Smyrna, Georgia (metropolitan Atlanta area).
	Our most advanced vaccines under development address the clade B subtype of the HIV virus that is most prevalent in the United States and the developed world.  Our vaccines are being evaluated to determine their potential to (a) prevent HIV infection and (b) to serve as a therapy for individuals who are already infected with HIV.  These vaccines are currently being evaluated in humans -- both in those infected with HIV and those who are not.
	As discussed in Note 2, the Company is a development-stage enterprise and we are devoting substantially all of our present efforts to research and development.  We have funded our activities to date from government grants and clinical trial assistance, and from sales of our equity securities. We will continue to require substantial funds to continue these activities.  We anticipate that our existing cash resources, combined with the proceeds from the NIH grant discussed in Note 3 and the financing events discussed in Note 11, should be sufficient to fund our operations into the first quarter of 2014.  In order to meet our operating cash flow requirements, we intend to conduct additional offerings of our equity securities or convertible debt instruments. We are also seeking additional funding for our research programs through government grant funding mechanisms.

Note_2_Summary_of_Significant_

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2012
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	2.           Summary of Significant Accounting Policies
	Basis of Presentation and Principles of Consolidation
	Our primary business is conducted by our wholly-owned subsidiary, GeoVax, Inc. The accompanying consolidated financial statements include the accounts of GeoVax, Inc. from inception together with those of GeoVax Labs, Inc. from September 28, 2006 (see Note 5).  All intercompany transactions have been eliminated in consolidation.
	Development-Stage Enterprise
	We are devoting all of our present efforts to research and development and GeoVax is a development stage enterprise as defined by Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 915, Development Stage Entities.  All losses accumulated since inception (June 27, 2001) have been considered as part of our development stage activities.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results may differ from those estimates.
	Cash and Cash Equivalents
	We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.  Our cash and cash equivalents consist primarily of bank deposits and money market accounts.  The recorded values approximate fair market values due to the short maturities.
	Fair Value of Financial Instruments and Concentration of Credit Risk
	Financial instruments that subject us to concentration of credit risk consist primarily of cash and cash equivalents, which are maintained by a high credit quality financial institution. The carrying values reported in the balance sheets for cash and cash equivalents approximate fair values.
	Property and Equipment
	Property and equipment are stated at cost, less accumulated depreciation and amortization.  The components of property and equipment as of December 31, 2012 and 2011 are as follows:
		2012			2011
	Laboratory equipment	$	388,000		$	388,000
	Leasehold improvements		115,605			115,605
	Other furniture, fixtures & equipment		28,685			28,685
	Total property and equipment		532,290			532,290
	Accumulated depreciation and amortization		(429,804	)		(356,084	)
	Property and equipment, net	$	102,486		$	176,206
	Expenditures for maintenance and repairs are charged to operations as incurred, while additions and improvements are capitalized.  Depreciation is computed using the straight-line method over the estimated useful lives of the assets which range from three to five years.  Amortization of leasehold improvements is computed using the straight-line method over the remaining term of the related lease.  Depreciation and amortization expense was $73,720, $84,131, and $94,887 during the years ended December 31, 2012, 2011 and 2010, respectively.
	Other Assets
	Other assets consist principally of license agreements for the use of technology obtained through the issuance of the Company’s common stock.  These license agreements are amortized on a straight line basis over ten years.  Amortization expense related to these agreements was $19,923, $24,886, and $24,886 during years ended December 31, 2012, 2011, and 2010, respectively, and is expected to be $10,000, $10,000, $-0-, $-0-, and $-0- for each of the next five years, respectively.
	Impairment of Long-Lived Assets
	We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future net cash flows expected to be generated by such assets.  If we consider such assets to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the expected future net cash flows from the assets.
	Accrued Liabilities
	As part of the process of preparing our financial statements, we estimate expenses that we believe we have incurred, but have not yet been billed by our third party vendors. This process involves identifying services and activities that have been performed by such vendors on our behalf and estimating the level to which they have been performed and the associated cost incurred for such service as of each balance sheet date in our financial statements. Examples of expenses for which we accrue include fees for professional services and fees owed to contract manufacturers in conjunction with the manufacture of vaccines for our clinical trials. We make these estimates based upon progress of activities related to contractual obligations and information received from vendors.
	Net Loss Per Share
	Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. All common share equivalents (which consist of options and warrants) are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. Common share equivalents which could potentially dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, totaled approximately 12.3 million, 2.8 million, and 2.0 million at December 31, 2012, 2011 and 2010, respectively.
	Revenue Recognition
	We recognize revenue in accordance with the SEC’s Staff Accounting Bulletin No. 101, Revenue Recognition in Financial Statements, as amended by Staff Accounting Bulletin No. 104, Revenue Recognition, (“SAB 104”). SAB 104 provides guidance in applying GAAP to revenue recognition issues, and specifically addresses revenue recognition for upfront, nonrefundable fees received in connection with research collaboration agreements.  During 2012, 2011 and 2010, our revenue consisted of grant funding received primarily from the NIH (see Note 3).  Revenue from this arrangement is approximately equal to the costs incurred and is recorded as income as the related costs are incurred.
	Research and Development Expense
	Research and development expense primarily consists of costs incurred in the discovery, development, testing and manufacturing of our product candidates. These expenses consist primarily of (i) fees paid to third-party service providers to perform, monitor and accumulate data related to our preclinical studies and clinical trials, (ii) costs related to sponsored research agreements, (iii) the costs to procure and manufacture materials used in clinical trials, (iv) laboratory supplies and facility-related expenses to conduct development, and (v) salaries, benefits, and share-based compensation for personnel.  These costs are charged to expense as incurred.
	Patent Costs
	Our expenditures relating to obtaining and protecting patents are charged to expense when incurred, and are included in general and administrative expense.
	Period to Period Comparisons
	Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not be relied upon as predictive of the results for future periods.  Certain prior year amounts have been reclassified to conform to the current year financial statement presentation.
	Income Taxes
	We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which temporary differences are expected to be recovered or settled.  Deferred tax assets are reduced by a valuation allowance unless, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will be realized.
	Stock-Based Compensation
	We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date.  Compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance.  Compensation cost for stock options or warrants is estimated at the grant date based on each instrument’s fair value as calculated by the Black-Scholes option pricing model.  We recognize stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award.  See Note 6 for additional stock-based compensation information.
	Recent Accounting Pronouncements
	There have been no recent accounting pronouncements or changes in accounting pronouncements which we expect to have a material impact on our financial statements, nor do we believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on our financial statements.

Note_3_Government_Grants

Note 3 - Government Grants	12 Months Ended
	Dec. 31, 2012
Government Grants [Abstract]	'
Government Grants [Text Block]	'
	3.           Government Grants
	NIH Grants
	In September 2007, the NIH awarded us an Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant to support our HIV/AIDS vaccine program.  We are utilizing this funding to further our HIV/AIDS vaccine development, optimization and production.  The original project period for the grant covered a five year period ending in August 2012, but was extended for an additional one year period.  The aggregate award totaled $20.4 million, with approximately $1.6 million remaining and available for use as of December 31, 2012.
	In September 2012, the NIH awarded us an additional grant of $1.9 million to support development of versions of our HIV/AIDS vaccines to address the clade C subtype of the HIV virus prevalent in the developing world.  The project period of this grant covers a one year period ending in August 2013.  There is approximately $1.4 million from this grant remaining and available for use as of December 31, 2012.
	We record revenue associated with these grants as the related costs and expenses are incurred and such revenue is reported as a separate line item in our statements of operations.  During 2012, 2011, and 2010, we recorded $2,657,327, $4,899,885, and $4,940,778, respectively, of revenue associated with these grants.
	QTDP Grant
	In November 2010, we were awarded a one-time grant of $244,479 pursuant to the Qualifying Therapeutic Discovery Project (QTDP) program enacted as part of the Patient Protection and Affordable Care Act of 2010.  The QTDP program was intended to provide incentive to smaller companies who are focusing on innovative therapeutic discoveries.  We received the full amount of the grant during 2010, which is recorded as revenue for 2010 in the accompanying Consolidated Statement of Operations.

Note_4_Commitments1

Note 4 - Commitments	12 Months Ended
	Dec. 31, 2012
Disclosure Text Block Supplement [Abstract]	'
Commitments Disclosure [Text Block]	'
	4.           Commitments
	Lease Agreements
	We lease approximately 8,400 square feet of office and laboratory space located in Smyrna, Georgia (metropolitan Atlanta). Rent expense for the years ended December 31, 2012, 2011 and 2010 was $118,801, $119,255, and $118,988, respectively.  Future minimum lease payments pursuant to the 62 month lease total $125,180 in 2013 and $128,920 in 2014.
	Other Commitments
	In the normal course of business, we may enter into various firm purchase commitments related to production and testing of our vaccine material, conduct of clinical trials, and other research-related activities. As of December 31, 2012, we had approximately $510,000 of unrecorded outstanding purchase commitments to our vendors and subcontractors, all of which we expect will be due in 2013.

Note_5_2006_Merger_and_Recapit

Note 5 - 2006 Merger and Recapitalization	12 Months Ended
	Dec. 31, 2012
Disclosure Text Block Supplement [Abstract]	'
Mergers, Acquisitions and Dispositions Disclosures [Text Block]	'
	5.           2006 Merger and Recapitalization
	The Company was originally incorporated in June 1988 under the laws of Illinois as Dauphin Technology, Inc. (“Dauphin”).  Dauphin was unsuccessful and its operations were terminated in December 2003.  In September 2006, Dauphin completed a merger (the “Merger”) with GeoVax, Inc. which was incorporated under the laws of Georgia in June 2001.  As a result of the Merger, the shareholders of GeoVax, Inc. exchanged their shares of common stock for Dauphin common stock and GeoVax, Inc. became a wholly-owned subsidiary of Dauphin.  Dauphin then changed its name to GeoVax Labs, Inc. and replaced its officers and directors with those of GeoVax, Inc.  Subsequent to the Merger, the Company has not conducted any business other than GeoVax, Inc.’s business of developing human vaccines.  The Merger was accounted for under the purchase method of accounting as a reverse acquisition in accordance with GAAP. Under this method of accounting, Dauphin was treated as the acquired company and, accordingly, all financial information prior to the date of Merger presented in the accompanying consolidated financial statements, or in the notes herein, as well as any references to prior operations, are those of GeoVax, Inc.  In June 2008, the Company was reincorporated under the laws of Delaware.

Note_7_Retirement_Plan

Note 7 - Retirement Plan	12 Months Ended
	Dec. 31, 2012
Compensation and Retirement Disclosure [Abstract]	'
Pension and Other Postretirement Benefits Disclosure [Text Block]	'
	7.           Retirement Plan
	We participate in a multi-employer defined contribution retirement plan (the “401k Plan”) administered by a third party service provider; and the Company contributes to the 401k Plan on behalf of its employees based upon a matching formula.  During the years ended December 31, 2012, 2011 and 2010 our contributions to the 401k Plan were $50,500, $56,928, and $52,632, respectively.

Note_10_Selected_Quarterly_Fin

Note 10 - Selected Quarterly Financial Data (unaudited)	12 Months Ended
	Dec. 31, 2012
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Financial Information [Text Block]	'
	10.           Selected Quarterly Financial Data (unaudited)
	A summary of selected quarterly financial data for 2012 and 2011 is as follows:
		2012 Quarter Ended
		31-Mar			30-Jun			30-Sep			31-Dec
	Revenue from grants	$	854,063		$	705,698		$	638,000		$	459,566
	Net loss		(730,513	)		(497,763	)		(296,779	)		(610,085	)
	Net loss per share		(0.04	)		(0.03	)		(0.02	)		(0.03	)
		2011 Quarter Ended
		31-Mar			30-Jun			30-Sep			31-Dec
	Revenue from grants	$	893,002		$	1,753,033		$	1,297,006		$	956,844
	Net loss		(606,282	)		(211,344	)		(375,852	)		(1,153,348	)
	Net loss per share		(0.04	)		(0.01	)		(0.02	)		(0.08	)

Note_11_Subsequent_Events

Note 11 - Subsequent Events	12 Months Ended
	Dec. 31, 2012
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	11.           Subsequent Events
	Warrant Modification and Exercise
	Effective January 17, 2013, we reduced the exercise price of our then-outstanding Series B Common Stock Purchase Warrants (see Note 6).  The exercise price for all the Series B Warrants was reduced from $0.75 to $0.60 per share.  The exercise price for the Series A Warrants and Series C Warrants that were issued concurrently with the Series B Warrants did not change.  In consideration for the reduction of the exercise price, the holders of the Series B Warrants immediately exercised 1,766,667 of the Series B Warrants for cash, resulting in total proceeds to the Company of $1,060,000.  The expiration date of Series B Warrants with respect to the remaining 1,166,667 shares was extended from March 21, 2013 to May 21, 2013.  In January 2013, we recorded general and administrative expense of $218,551 associated with the warrant modifications.

Schedule_II_Valuation_and_Qual

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2012
Valuation and Qualifying Accounts [Abstract]	'
Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]	'
	SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTS
	For the Years Ended December 31, 2012, 2011 and 2010
					Additions
	Description		Balance at		Charged to		Charged to		-1			Balance at
			Beginning		Costs and		Other		Deductions			End
			Of Period		Expenses		Accounts					Of Period
	Reserve Deducted in the Balance Sheet
	From the Asset to Which it Applies:
	Allowance for Deferred Tax Assets
	Year ended December 31, 2012		$	27,591,230	$	796,237	$	-	$	(1,112,961	)	$	27,274,506
	Year ended December 31, 2011			27,576,253		888,561		-		(873,584	)		27,591,230
	Year ended December 31, 2010			27,091,338		1,160,405		-		(675,490	)		27,576,253
		-1	Deductions represent the effect of expiring NOL carryforwards from prior years.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2012
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	Basis of Presentation and Principles of Consolidation
	Our primary business is conducted by our wholly-owned subsidiary, GeoVax, Inc. The accompanying consolidated financial statements include the accounts of GeoVax, Inc. from inception together with those of GeoVax Labs, Inc. from September 28, 2006 (see Note 5).  All intercompany transactions have been eliminated in consolidation.
Development-Stage Enterprise [Policy Text Block]	'
	Stage Enterprise
	We are devoting all of our present efforts to research and development and GeoVax is a development stage enterprise as defined by Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 915, Development Stage Entities.  All losses accumulated since inception (June 27, 2001) have been considered as part of our development stage activities.
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results may differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash and Cash Equivalents
	We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.  Our cash and cash equivalents consist primarily of bank deposits and money market accounts.  The recorded values approximate fair market values due to the short maturities.
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair Value of Financial Instruments and Concentration of Credit Risk
	Financial instruments that subject us to concentration of credit risk consist primarily of cash and cash equivalents, which are maintained by a high credit quality financial institution. The carrying values reported in the balance sheets for cash and cash equivalents approximate fair values.
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property and Equipment
	Property and equipment are stated at cost, less accumulated depreciation and amortization.  The components of property and equipment as of December 31, 2012 and 2011 are as follows:
		2012			2011
	Laboratory equipment	$	388,000		$	388,000
	Leasehold improvements		115,605			115,605
	Other furniture, fixtures & equipment		28,685			28,685
	Total property and equipment		532,290			532,290
	Accumulated depreciation and amortization		(429,804	)		(356,084	)
	Property and equipment, net	$	102,486		$	176,206
	Expenditures for maintenance and repairs are charged to operations as incurred, while additions and improvements are capitalized.  Depreciation is computed using the straight-line method over the estimated useful lives of the assets which range from three to five years.  Amortization of leasehold improvements is computed using the straight-line method over the remaining term of the related lease.  Depreciation and amortization expense was $73,720, $84,131, and $94,887 during the years ended December 31, 2012, 2011 and 2010, respectively.
Other Assets [Policy Text Block]	'
	Other Assets
	Other assets consist principally of license agreements for the use of technology obtained through the issuance of the Company’s common stock.  These license agreements are amortized on a straight line basis over ten years.  Amortization expense related to these agreements was $19,923, $24,886, and $24,886 during years ended December 31, 2012, 2011, and 2010, respectively, and is expected to be $10,000, $10,000, $-0-, $-0-, and $-0- for each of the next five years, respectively.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	'
	Impairment of Long-Lived Assets
	We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future net cash flows expected to be generated by such assets.  If we consider such assets to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the expected future net cash flows from the assets.
Accrued Liabilities [Policy Text Block]	'
	Accrued Liabilities
	As part of the process of preparing our financial statements, we estimate expenses that we believe we have incurred, but have not yet been billed by our third party vendors. This process involves identifying services and activities that have been performed by such vendors on our behalf and estimating the level to which they have been performed and the associated cost incurred for such service as of each balance sheet date in our financial statements. Examples of expenses for which we accrue include fees for professional services and fees owed to contract manufacturers in conjunction with the manufacture of vaccines for our clinical trials. We make these estimates based upon progress of activities related to contractual obligations and information received from vendors.
Earnings Per Share, Policy [Policy Text Block]	'
	Net Loss Per Share
	Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. All common share equivalents (which consist of options and warrants) are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. Common share equivalents which could potentially dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, totaled approximately 12.3 million, 2.8 million, and 2.0 million at December 31, 2012, 2011 and 2010, respectively.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition
	We recognize revenue in accordance with the SEC’s Staff Accounting Bulletin No. 101, Revenue Recognition in Financial Statements, as amended by Staff Accounting Bulletin No. 104, Revenue Recognition, (“SAB 104”). SAB 104 provides guidance in applying GAAP to revenue recognition issues, and specifically addresses revenue recognition for upfront, nonrefundable fees received in connection with research collaboration agreements.  During 2012, 2011 and 2010, our revenue consisted of grant funding received primarily from the NIH (see Note 3).  Revenue from this arrangement is approximately equal to the costs incurred and is recorded as income as the related costs are incurred.
Research and Development Expense, Policy [Policy Text Block]	'
	Research and Development Expense
	Research and development expense primarily consists of costs incurred in the discovery, development, testing and manufacturing of our product candidates. These expenses consist primarily of (i) fees paid to third-party service providers to perform, monitor and accumulate data related to our preclinical studies and clinical trials, (ii) costs related to sponsored research agreements, (iii) the costs to procure and manufacture materials used in clinical trials, (iv) laboratory supplies and facility-related expenses to conduct development, and (v) salaries, benefits, and share-based compensation for personnel.  These costs are charged to expense as incurred.
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	'
	Patent Costs
	Our expenditures relating to obtaining and protecting patents are charged to expense when incurred, and are included in general and administrative expense.
Period to Period Comparisons [Policy Text Block]	'
	Period to Period Comparisons
	Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not be relied upon as predictive of the results for future periods.  Certain prior year amounts have been reclassified to conform to the current year financial statement presentation.
Income Tax, Policy [Policy Text Block]	'
	Income Taxes
	We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which temporary differences are expected to be recovered or settled.  Deferred tax assets are reduced by a valuation allowance unless, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will be realized.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-Based Compensation
	We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date.  Compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance.  Compensation cost for stock options or warrants is estimated at the grant date based on each instrument’s fair value as calculated by the Black-Scholes option pricing model.  We recognize stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award.  See Note 6 for additional stock-based compensation information.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recent Accounting Pronouncements
	There have been no recent accounting pronouncements or changes in accounting pronouncements which we expect to have a material impact on our financial statements, nor do we believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on our financial statements.

Note_5_Stockholders_Equity_Tab

Note 5 - Stockholders' Equity (Tables)	9 Months Ended						12 Months Ended
	Sep. 30, 2013						Dec. 31, 2012
Stockholders' Equity Note [Abstract]	'						'
Common Stock Reserved For Future Issuance [Table Text Block]	'						'
	Common Stock Purchase Warrants		8,292,226
	Equity Incentive Plans		1,197,529
	Series A Convertible Preferred Stock		1,050,667
	Total		10,540,422
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'						'
		Number of Shares			Weighted Average			Number			Weighted-			Weighted-			Aggregate
					Exercise Price			of Shares			Average			Average			Intrinsic
	Outstanding at December 31, 2012		1,069,141		$	4.5					Exercise			Remaining			Value
	Granted		--			--					Price			Contractual
	Exercised		--			--								Term (yrs)
	Forfeited or expired		(78,429	)		4.86	Outstanding at December 31, 2011		928,242		$	5.43
	Outstanding at September 30, 2013		990,712		$	4.47	Granted		238,500			0.7
	Exercisable at September 30, 2013		679,036		$	6.14	Exercised		-			-
							Forfeited or expired		(97,601	)		4.02
							Outstanding at December 31, 2012		1,069,141		$	4.5			6.2		$	-0-
							Exercisable at December 31, 2012		698,995		$	6.38			4.6		$	-0-
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'						'
		Number of Shares			Weighted Average			Number of Shares			Weighted Average
					Exercise Price						Exercise Price
	Outstanding at December 31, 2012		11,225,559		$	2.06	Outstanding at December 31, 2011		1,870,559		$	7.96
	Issued		--			--	Issued – Series A Warrants (1)		2,933,333			1
	Exercised		(2,933,333	)		0.56	Issued – Series B Warrants (1)		2,933,333			0.75
	Forfeited or expired		--			--	Issued – Series C Warrants (1)		2,933,333			1
	Outstanding at September 30, 2013		8,292,226		$	2.53	Issued – Other Warrants (2)		612,001			1
	Exercisable at September 30, 2013		8,292,226		$	2.53	Exercised		--			--
							Forfeited or expired		(57,000	)		7
							Outstanding at December 31, 2012		11,225,559		$	2.06
							Exercisable at December 31, 2012		8,290,376		$	2.44
Allocation of Net Proceeds from Preferred Stock Financing [Table Text Block]	'						'
							Net proceeds after transaction costs	$	1,999,032
							Less:       Fair value of warrants (recorded to Additional Paid-in Capital)		(1,127,418	)
							Beneficial conversion feature (recorded to Additional Paid-in Capital)		(762,667	)
							Net proceeds allocated to preferred stock		108,947
							Accretion of beneficial conversion feature (deemed dividend)		762,667
							Initial carrying value of preferred stock		871,614
							Conversions to common stock		(559,418	)
							Carrying value of preferred stock at December 31, 2012	$	312,196
Additional Information Concerning Stock Options [Table Text Block]	'						'
								2012			2011			2010
							Weighted average fair value of options granted during the period	$	0.59		$	0.79		$	2.95
							Intrinsic value of options exercised during the period		-			-			-
							Total fair value of options vested during the period		319,920			540,339			499,557
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'						'
								2012			2011			2010
							Weighted average risk-free interest rates		1.1	%		1.4	%		2.6	%
							Expected dividend yield		0	%		0	%		0	%
							Expected life of option (yrs)	6.7			7			6.7
							Expected volatility		105.2	%		111.2	%		112.9	%
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'						'
								2012			2011			2010
							General and administrative expense	$	231,936		$	284,352		$	369,161
							Research and development expense		78,140			179,400			206,501
							Total stock option expense	$	310,076		$	463,752		$	575,662

Note_2_Summary_of_Significant_1

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2012
Accounting Policies [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
		2012			2011
	Laboratory equipment	$	388,000		$	388,000
	Leasehold improvements		115,605			115,605
	Other furniture, fixtures & equipment		28,685			28,685
	Total property and equipment		532,290			532,290
	Accumulated depreciation and amortization		(429,804	)		(356,084	)
	Property and equipment, net	$	102,486		$	176,206

Note_8_Income_Taxes_Tables

Note 8 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
		2012			2011
	Deferred tax assets:
	Net operating loss carryforward	$	24,429,472		$	24,872,082
	Research and development tax credit carryforward		763,965			763,690
	Stock-based compensation expense		2,097,194			1,991,769
	Total deferred tax assets		27,290,631			27,627,541
	Deferred tax liabilities
	Depreciation		(16,125	)		(36,311	)
	Total deferred tax liabilities		(16,125	)		(36,311	)
	Net deferred tax assets		27,274,506			27,591,230
	Valuation allowance		(27,274,506	)		(27,591,230	)
		$	-		$	-
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
		2012			2011			2010
	U.S. federal statutory rate applied to pretax loss	$	(725,948	)	$	(797,921	)	$	(934,092	)
	Permanent differences		2,674			4,216			(77,200	)
	Research and development credits		-			32,675			59,959
	Change in valuation allowance		723,274			761,030			951,333
	Reported income tax expense	$	-		$	-		$	-

Note_10_Selected_Quarterly_Fin1

Note 10 - Selected Quarterly Financial Data (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2012
Quarterly Financial Information Disclosure [Abstract]	'
Schedule of Quarterly Financial Information [Table Text Block]	'
		2012 Quarter Ended
		31-Mar			30-Jun			30-Sep			31-Dec
	Revenue from grants	$	854,063		$	705,698		$	638,000		$	459,566
	Net loss		(730,513	)		(497,763	)		(296,779	)		(610,085	)
	Net loss per share		(0.04	)		(0.03	)		(0.02	)		(0.03	)
		2011 Quarter Ended
		31-Mar			30-Jun			30-Sep			31-Dec
	Revenue from grants	$	893,002		$	1,753,033		$	1,297,006		$	956,844
	Net loss		(606,282	)		(211,344	)		(375,852	)		(1,153,348	)
	Net loss per share		(0.04	)		(0.01	)		(0.02	)		(0.08	)

Note_3_Basic_and_Diluted_Loss_1

Note 3 - Basic and Diluted Loss Per Common Share (Details)	9 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Earnings Per Share [Abstract]	'	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)	10.3	13.2	12.3	2.8	2

Note_4_Commitments_Details

Note 4 - Commitments (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
	sqm	sqft
	sqft
Commitments and Contingencies Disclosure [Abstract]	'	'
Area of Real Estate Property (in Square Meters)	8,400	8,400
Operating Lease, Term of Lease	'62 months	'62 months
Operating Leases, Future Minimum Payments, Remainder of Fiscal Year	$31,760	'
Operating Leases, Future Minimum Payments, Due in Two Years	128,920	128,920
Unrecorded Unconditional Purchase Obligation	$59,985	$510,000

Note_5_Stockholders_Equity_Det

Note 5 - Stockholders' Equity (Details) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

138 Months Ended

147 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

12 Months Ended

31-May-13

Jan. 31, 2013

Feb. 28, 2010

Jun. 30, 2013

Mar. 31, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2012

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2007

Dec. 31, 2006

Dec. 31, 2005

Dec. 31, 2004

Dec. 31, 2003

Dec. 31, 2002

Dec. 31, 2012

Sep. 30, 2013

Aug. 01, 2013

Jun. 10, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2006

14-May-13

Jan. 17, 2013

31-May-13

Jan. 31, 2013

Dec. 31, 2012

13-May-13

Jan. 16, 2013

Dec. 31, 2012

Dec. 31, 2012

Jan. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2012

Dec. 31, 2012

Sep. 30, 2013

Mar. 31, 2012

Dec. 31, 2011

Dec. 31, 2006

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series A Warrants [Member]

Series C Warrants [Member]

Individual Accredited Investors [Member]

Individual Accredited Investors [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Maximum [Member]

Common Stock Issued for Services [Member]

Common Stock Issued for Services [Member]

Common Stock Issued for Services [Member]

Compensatory Warrants [Member]

Compensatory Warrants [Member]

Compensatory Warrants [Member]

Note 5 - Stockholders' Equity (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares Authorized (in Shares)

'

'

'

'

'

75,000,000

40,000,000

'

40,000,000

40,000,000

'

'

'

'

'

'

'

'

'

40,000,000

75,000,000

75,000,000

40,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares, Outstanding (in Shares)

'

'

'

'

'

21,666,610

18,733,277

'

18,733,277

16,442,611

'

'

'

'

'

'

'

'

'

18,733,277

21,666,610

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues (in Shares)

1,166,666

1,766,667

12,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

407,999

658,520

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Warrant Exercises (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$583,333

$1,060,000

$583,333

$1,060,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation

'

'

'

'

'

116,600

'

247,318

310,076

772,997

750,532

'

'

'

'

'

'

'

'

6,669,815

6,634,289

'

'

33,348

84,742

116,600

247,318

310,076

463,752

575,662

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized

'

'

'

'

'

'

271,901

'

271,901

'

'

'

'

'

'

'

'

'

'

271,901

'

'

'

135,418

'

135,418

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

'

'

'

'

'

'

'

'

'2 years 36 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'1 year 255 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.5

0.6

'

'

0.75

0.6

0.75

1

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercises (in Shares)

'

'

'

'

'

-2,933,333

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,166,666

1,766,667

'

1,766,667

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Outstanding (in Shares)

'

'

'

'

'

8,292,226

11,225,559

'

11,225,559

1,870,559

'

'

'

'

'

'

'

'

'

11,225,559

8,292,226

'

'

'

'

'

'

'

'

'

'

'

1,166,667

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other General and Administrative Expense (in Dollars)

'

'

'

19,617

218,551

238,169

'

'

'

152,126

'

'

'

'

'

'

'

'

'

'

390,295

'

'

'

'

'

'

'

'

'

'

'

'

'

218,551

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Authorized (in Shares)

'

'

'

'

'

10,000,000

10,000,000

'

10,000,000

10,000,000

'

'

'

'

'

'

'

'

'

10,000,000

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,200

2,200

'

'

'

'

Preferred Stock, Par or Stated Value Per Share (in Dollars per share)

'

'

'

'

'

$0.01

$0.01

'

$0.01

$0.01

'

'

'

'

'

'

'

'

'

$0.01

$0.01

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

(in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,000

$1,000

$1,000

'

$1,000

'

Proceeds from Issuance of Preferred Stock and Preference Stock

'

'

'

'

'

'

1,999,032

1,999,032

1,999,032

'

'

'

'

'

'

'

'

'

'

2,727,475

2,727,475

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,200,000

'

'

'

'

Proceeds from Issuance of Convertible Preferred Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

Convertible Preferred Stock, Conversion Price Per Share (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.75

'

'

Convertible Preferred Stock, Total Conversion Shares (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,050,667

1,050,667

'

2,933,333

'

'

Number of Preferred Shares Converted into Common Stock (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,412

'

'

'

'

'

Stock Issued During Period, Shares, Conversion of Convertible Securities (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,882,667

'

'

'

'

'

Preferred Stock, Shares Outstanding (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

788

788

788

'

0

'

Class of Warrant or Right, Percentage of Conversion Shares Could Be Purchased

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

100.00%

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,933,333

'

'

'

'

'

'

'

'

'

'

'

'

8,799,999

8,799,999

'

'

'

'

Other Accrued Liabilities, Current

'

'

'

'

'

'

'

'

'

'

'

90,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, New Issues

'

'

'

'

'

'

'

'

273,360

441,210

90,000

1,520,000

1,771,091

3,162,950

'

'

239,919

2,459,609

470

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

273,360

441,210

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Common Stock

'

'

'

'

'

1,643,333

'

310,160

310,160

404,410

'

'

'

'

500,000

1,500,000

750,000

'

'

15,836,468

17,479,801

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

36,800

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,933,333

[1]

'

'

2,933,333

[1]

2,933,333

[1]

'

987,783

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Issued During Period, Exercise Price (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1

$1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of Warrants Issued During Period (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

612,001

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Issued for Services (in Shares)

'

'

'

'

'

'

'

'

0

129,245

10,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Allocated Share-based Compensation Expense

'

'

'

'

'

'

'

'

$310,076

$463,752

$575,662

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0

$150,000

$53,813

$0

$7,119

$121,057

$231,936

$284,352

$369,161

'

'

'

'

'

'

Minimum Option Exercise Price as Percentage of Fair Value of ISO's Granted to Certain Employees

'

'

'

'

'

'

'

'

'

'

'

'

'

'

110.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term

'

'

'

'

'

'

'

'

'6 years 255 days

'7 years

'6 years 255 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

[1]

See discussion under "Series A Convertible Preferred Stock" above.

Note_5_Stockholders_Equity_Det1

Note 5 - Stockholders' Equity (Details) - Common Stock Reserved for Future Issuance	Sep. 30, 2013
Note 5 - Stockholders' Equity (Details) - Common Stock Reserved for Future Issuance [Line Items]	'
Common Stock Reserved for Future Issuance	10,540,422
Common Stock Purchase Warrants [Member]	'
Note 5 - Stockholders' Equity (Details) - Common Stock Reserved for Future Issuance [Line Items]	'
Common Stock Reserved for Future Issuance	8,292,226
Equity Incentive Plans [Member]	'
Note 5 - Stockholders' Equity (Details) - Common Stock Reserved for Future Issuance [Line Items]	'
Common Stock Reserved for Future Issuance	1,197,529
Series A Convertible Preferred Stock [Member]	'
Note 5 - Stockholders' Equity (Details) - Common Stock Reserved for Future Issuance [Line Items]	'
Common Stock Reserved for Future Issuance	1,050,667

Note_5_Stockholders_Equity_Det2

Note 5 - Stockholders' Equity (Details) - Share-based Compensation, Stock Options, Activity (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2010
Share-based Compensation, Stock Options, Activity [Abstract]	'	'	'
Outstanding	1,069,141	'	928,242
Outstanding (in Dollars per share)	$4.50	'	$5.43
Exercisable at September 30, 2013	679,036	698,995	'
Exercisable at September 30, 2013 (in Dollars per share)	$6.14	$6.38	'
Forfeited or expired	-78,429	97,601	'
Forfeited or expired (in Dollars per share)	$4.86	$4.02	'
Outstanding	990,712	1,069,141	928,242
Outstanding (in Dollars per share)	$4.47	$4.50	$5.43

Note_5_Stockholders_Equity_Det3

Note 5 - Stockholders' Equity (Details) - Stockholders' Equity Note, Warrants (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Stockholders' Equity Note, Warrants [Abstract]	'	'
Outstanding (in Shares)	11,225,559	1,870,559
Outstanding (in Dollars per share)	$2.06	$7.96
Exercisable at September 30, 2013	8,292,226	8,290,376
Exercisable at September 30, 2013 (in Dollars per share)	$2.53	$2.44
Exercised	-2,933,333	0
Exercised (in Dollars per share)	$0.56	$0
Outstanding (in Shares)	8,292,226	11,225,559
Outstanding (in Dollars per share)	$2.53	$2.06

Note_6_Income_Taxes_Details

Note 6 - Income Taxes (Details) (USD $)	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	$69,800,000	'
Deferred Tax Assets, Tax Credit Carryforwards, Research	$764,000	$763,690

Note_7_NIH_Grant_Funding_Detai

Note 7 - NIH Grant Funding (Details) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

138 Months Ended

147 Months Ended

59 Months Ended

71 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2011

Sep. 30, 2011

Jun. 30, 2011

Mar. 31, 2011

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2012

Sep. 30, 2013

Aug. 31, 2012

Aug. 31, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2012

Aug. 31, 2013

Dec. 31, 2012

Jul. 31, 2013

Sep. 30, 2013

First NIH Grant [Member]

First NIH Grant [Member]

First NIH Grant [Member]

First NIH Grant [Member]

Second NIH Grant [Member]

Second NIH Grant [Member]

Second NIH Grant [Member]

Third NIH Grant [Member]

Third NIH Grant [Member]

Note 7 - NIH Grant Funding (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Grant Award

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$20,400,000

$20,400,000

'

'

'

$1,900,000

'

$277,000

'

Unused Grant Funds

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

773,000

1,600,000

'

'

1,400,000

'

249,000

Revenue from Grants

$1,004,211

$459,566

$638,000

$705,698

$854,063

$956,844

$1,297,006

$1,753,033

$893,002

$2,242,812

$2,197,761

$2,657,327

$4,899,885

$5,185,257

$22,969,019

$25,211,831

'

'

'

'

$1,900,000

'

'

'

'

Project Period Covered by Grants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'1 year

'

'2 years

'

Note_8_Related_Party_Transacti1

Note 8 - Related Party Transactions (Details) (USD $)

1 Months Ended

9 Months Ended

12 Months Ended

138 Months Ended

147 Months Ended

1 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

31-May-13

Jan. 31, 2013

Feb. 28, 2010

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2006

Dec. 31, 2005

Dec. 31, 2004

Dec. 31, 2012

Sep. 30, 2013

Jan. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Members of Board of Directors and Management [Member]

Ongoing Patent Cost Reimbursements [Member]

Ongoing Patent Cost Reimbursements [Member]

Ongoing Patent Cost Reimbursements [Member]

Ongoing Patent Cost Reimbursements [Member]

Research Agreements [Member]

Research Agreements [Member]

Research Agreements [Member]

Research Agreements [Member]

Consulting Agreement [Member]

Consulting Agreement [Member]

Consulting Agreement [Member]

Note 8 - Related Party Transactions (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Related Party Transaction, Expenses from Transactions with Related Party

'

'

'

'

'

'

'

'

'

'

'

'

'

$24,115

$89,885

$249,907

$193,674

$252,478

$552,403

$1,172,758

$1,391,203

$24,000

$24,000

$57,600

Stock Issued During Period, Shares, New Issues (in Shares)

1,166,666

1,766,667

12,000

'

'

'

'

'

'

'

'

'

380,954

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Common Stock

'

'

'

$1,643,333

$310,160

$310,160

$404,410

$500,000

$1,500,000

$750,000

$15,836,468

$17,479,801

$255,239

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Purchase Period

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

571,432

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)

'

'

'

'

'

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

'

'

'

'

Note_2_Summary_of_Significant_2

Note 2 - Summary of Significant Accounting Policies (Details) (USD $)	9 Months Ended		12 Months Ended
Share data in Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'	'
Depreciation (in Dollars)	'	'	$73,720	$84,131	$94,887
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)	10.3	13.2	12.3	2.8	2
Licensing Agreements [Member]	'	'	'	'	'
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'	'
Finite-Lived Intangible Asset, Useful Life	'	'	'	'	'10 years
Amortization of Intangible Assets (in Dollars)	'	'	19,923	24,886	24,886
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months (in Dollars)	'	'	10,000	'	'
Finite-Lived Intangible Assets, Amortization Expense, Year Two (in Dollars)	'	'	10,000	'	'
Finite-Lived Intangible Assets, Amortization Expense, Year Three (in Dollars)	'	'	0	'	'
Finite-Lived Intangible Assets, Amortization Expense, Year Four (in Dollars)	'	'	0	'	'
Finite-Lived Intangible Assets, Amortization Expense, Year Five (in Dollars)	'	'	$0	'	'
Minimum [Member]	'	'	'	'	'
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'	'
Property, Plant and Equipment, Useful Life	'	'	'3 years	'	'
Maximum [Member]	'	'	'	'	'
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'	'
Property, Plant and Equipment, Useful Life	'	'	'5 years	'	'

Note_2_Summary_of_Significant_3

Note 2 - Summary of Significant Accounting Policies (Details) - Property and Equipment (USD $)	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	'	$532,290	$532,290
Accumulated depreciation and amortization	-474,956	-429,804	-356,084
Property and equipment, net	143,936	102,486	176,206
Laboratory Equipment [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	'	388,000	388,000
Leasehold Improvements [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	'	115,605	115,605
Other Furniture, Fixtures and Equipment [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	'	$28,685	$28,685

Note_3_Government_Grants_Detai

Note 3 - Government Grants (Details) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

138 Months Ended

147 Months Ended

12 Months Ended

59 Months Ended

71 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2011

Sep. 30, 2011

Jun. 30, 2011

Mar. 31, 2011

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2012

Sep. 30, 2013

Aug. 31, 2013

Aug. 31, 2012

Aug. 31, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2012

Aug. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2010

First NIH Grant [Member]

First NIH Grant [Member]

First NIH Grant [Member]

First NIH Grant [Member]

First NIH Grant [Member]

Second NIH Grant [Member]

Second NIH Grant [Member]

Second NIH Grant [Member]

NIH Grants [Member]

NIH Grants [Member]

NIH Grants [Member]

QTDP Grant [Member]

Note 3 - Government Grants (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Project Period Covered by Grants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'1 year

'

'

'

'

'

Project Extension Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'1 year

'

'

'

'

'

'

'

'

'

'

'

Grant Award

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$20,400,000

$20,400,000

'

'

'

$1,900,000

'

'

'

'

$244,479

Unused Grant Funds

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

773,000

1,600,000

'

'

1,400,000

'

'

'

'

Revenue from Grants

$1,004,211

$459,566

$638,000

$705,698

$854,063

$956,844

$1,297,006

$1,753,033

$893,002

$2,242,812

$2,197,761

$2,657,327

$4,899,885

$5,185,257

$22,969,019

$25,211,831

'

'

'

'

'

$1,900,000

'

'

$2,657,327

$4,899,885

$4,940,778

'

Note_4_Commitments_Details1

Note 4 - Commitments (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
	sqm	sqft
	sqft
Disclosure Text Block Supplement [Abstract]	'	'	'	'
Area of Real Estate Property (in Square Feet)	8,400	8,400	'	'
Operating Leases, Rent Expense	'	$118,801	$119,255	$118,988
Operating Lease, Term of Lease	'62 months	'62 months	'	'
Operating Leases, Future Minimum Payments Due, Next Twelve Months	'	125,180	'	'
Operating Leases, Future Minimum Payments, Due in Two Years	128,920	128,920	'	'
Unrecorded Unconditional Purchase Obligation	$59,985	$510,000	'	'

Note_6_Stockholders_Equity_Det

Note 6 - Stockholders' Equity (Details) - Allocation of Net Proceeds from Preferred Stock Financing (USD $)	9 Months Ended		12 Months Ended	138 Months Ended	147 Months Ended
	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2012	Sep. 30, 2013	Mar. 31, 2012
Allocation of Net Proceeds from Preferred Stock Financing [Abstract]	'	'	'	'	'	'
Net proceeds after transaction costs	$1,999,032	$1,999,032	$1,999,032	$2,727,475	$2,727,475	'
Less: Fair value of warrants (recorded to Additional Paid-in Capital)	-1,127,418	'	'	'	'	'
Beneficial conversion feature (recorded to Additional Paid-in Capital)	-762,667	'	'	'	'	'
Net proceeds allocated to preferred stock	108,947	'	'	'	'	'
Accretion of beneficial conversion feature (deemed dividend)	762,667	'	'	'	'	'
Carrying value	312,196	'	312,196	312,196	312,196	871,614
Conversions to common stock	($559,418)	'	'	'	'	'

Note_6_Stockholders_Equity_Det1

Note 6 - Stockholders' Equity (Details) - Stock Option Activity (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2010
Stock Option Activity [Abstract]	'	'	'
Outstanding	1,069,141	'	928,242
Outstanding (in Dollars per share)	$4.50	'	$5.43
Outstanding	'	'6 years 73 days	'
Outstanding (in Dollars)	$0	'	'
Exercisable at December 31, 2012	679,036	698,995	'
Exercisable at December 31, 2012 (in Dollars per share)	$6.14	$6.38	'
Exercisable at December 31, 2012	'	'4 years 219 days	'
Exercisable at December 31, 2012 (in Dollars)	'	0	'
Granted	'	238,500	'
Granted (in Dollars per share)	'	$0.70	'
Exercised	'	0	'
Exercised (in Dollars per share)	'	$0	'
Forfeited or expired	78,429	-97,601	'
Forfeited or expired (in Dollars per share)	$4.86	$4.02	'
Outstanding	990,712	1,069,141	928,242
Outstanding (in Dollars per share)	$4.47	$4.50	$5.43
Outstanding	'	'6 years 73 days	'
Outstanding (in Dollars)	'	$0	'

Note_6_Stockholders_Equity_Det2

Note 6 - Stockholders' Equity (Details) - Additional Information Concerning Stock Options (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Additional Information Concerning Stock Options [Abstract]	'	'	'
Weighted average fair value of options granted during the period (in Dollars per share)	$0.59	$0.79	$2.95
Total fair value of options vested during the period	$319,920	$540,339	$499,557

Note_6_Stockholders_Equity_Det3

Note 6 - Stockholders' Equity (Details) - Significant Assumptions Used in Fair Value Calculations	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Significant Assumptions Used in Fair Value Calculations [Abstract]	'	'	'
Weighted average risk-free interest rates	1.10%	1.40%	2.60%
Expected dividend yield	0.00%	0.00%	0.00%
Expected life of option (yrs)	'6 years 255 days	'7 years	'6 years 255 days
Expected volatility	105.20%	111.20%	112.90%

Note_6_Stockholders_Equity_Det4

Note 6 - Stockholders' Equity (Details) - Stock-based Compensation Expense (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock option expense	$310,076	$463,752	$575,662
General and Administrative Expense [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock option expense	231,936	284,352	369,161
Research and Development Expense [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock option expense	$78,140	$179,400	$206,501

Note_6_Stockholders_Equity_Det5

Note 6 - Stockholders' Equity (Details) - Stock Purchase Warrant Transactions (USD $)

9 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

14-May-13

Jan. 17, 2013

Jan. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Series A Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series C Warrants [Member]

Other Warrants [Member]

Class of Warrant or Right [Line Items]

'

'

'

'

'

'

'

'

'

'

Outstanding (in Shares)

8,292,226

11,225,559

1,870,559

'

'

1,166,667

'

'

'

'

Outstanding (in Dollars per share)

$2.53

$2.06

$7.96

'

'

'

'

'

'

'

Exercisable at December 31, 2012 (in Shares)

8,292,226

8,290,376

'

'

'

'

'

'

'

'

Exercisable at December 31, 2012

$2.53

$2.44

'

'

'

'

'

'

'

'

Number of Shares (in Dollars)

'

'

'

$2,933,333

[1]

'

'

'

$2,933,333

[1]

$2,933,333

[1]

$612,001

[2]

Weighted Average Exercise Price

'

'

'

$1

[1]

'

'

'

$0.75

[1]

$1

[1]

$1

[2]

Exercised (in Shares)

-2,933,333

0

'

'

1,166,666

1,766,667

1,766,667

'

'

'

Exercised

$0.56

$0

'

'

'

'

'

'

'

'

Forfeited or expired (in Shares)

'

-57,000

'

'

'

'

'

'

'

'

Forfeited or expired

'

$7

'

'

'

'

'

'

'

'

[1]

See discussion under "Series A Convertible Preferred Stock" above.

[2]

See discussion under "Common Stock Transactions" above.

Note_7_Retirement_Plan_Details

Note 7 - Retirement Plan (Details) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Compensation and Retirement Disclosure [Abstract]	'	'	'
Defined Contribution Plan, Employer Discretionary Contribution Amount	$50,500	$56,928	$52,632

Note_8_Income_Taxes_Details_De

Note 8 - Income Taxes (Details) - Deferred Tax Assets and Liabilities (USD $)	Dec. 31, 2012	Dec. 31, 2011
Deferred tax assets:	'	'
Net operating loss carryforward	$24,429,472	$24,872,082
Research and development tax credit carryforward	764,000	763,690
Stock-based compensation expense	2,097,194	1,991,769
Total deferred tax assets	27,290,631	27,627,541
Deferred tax liabilities	'	'
Depreciation	-16,125	-36,311
Total deferred tax liabilities	-16,125	-36,311
Net deferred tax assets	27,274,506	27,591,230
Valuation allowance	($27,274,506)	($27,591,230)

Note_8_Income_Taxes_Details_Re

Note 8 - Income Taxes (Details) - Reconciliation of the Income Tax Benefit (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Reconciliation of the Income Tax Benefit [Abstract]	'	'	'
U.S. federal statutory rate applied to pretax loss	($725,948)	($797,921)	($934,092)
Permanent differences	2,674	4,216	-77,200
Research and development credits	'	32,675	59,959
Change in valuation allowance	$723,274	$761,030	$951,333

Note_10_Selected_Quarterly_Fin2

Note 10 - Selected Quarterly Financial Data (unaudited) (Details) - Selected Quarterly Financial Data (USD $)

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

138 Months Ended

147 Months Ended

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2011

Sep. 30, 2011

Jun. 30, 2011

Mar. 31, 2011

Dec. 31, 2001

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2007

Dec. 31, 2006

Dec. 31, 2005

Dec. 31, 2004

Dec. 31, 2003

Dec. 31, 2002

Dec. 31, 2012

Sep. 30, 2013

Selected Quarterly Financial Data [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenue from grants

$1,004,211

$459,566

$638,000

$705,698

$854,063

$956,844

$1,297,006

$1,753,033

$893,002

'

$2,242,812

$2,197,761

$2,657,327

$4,899,885

$5,185,257

'

'

'

'

'

'

'

'

$22,969,019

$25,211,831

Net loss

($190,148)

($610,085)

($296,779)

($497,763)

($730,513)

($1,153,348)

($375,852)

($211,344)

($606,282)

($170,592)

($1,413,229)

($1,525,055)

($2,135,140)

($2,346,826)

($2,747,328)

($3,284,252)

($3,728,187)

($4,241,796)

($584,166)

($1,611,086)

($2,351,828)

($947,804)

($618,137)

($24,767,142)

($26,180,371)

Net loss per share (in Dollars per share)

'

($0.03)

($0.02)

($0.03)

($0.04)

($0.08)

($0.02)

($0.01)

($0.04)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Note_11_Subsequent_Events_Deta

Note 11 - Subsequent Events (Details) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

147 Months Ended

0 Months Ended

1 Months Ended

Jun. 30, 2013

Mar. 31, 2013

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2011

Sep. 30, 2013

14-May-13

Jan. 17, 2013

31-May-13

Jan. 31, 2013

13-May-13

Jan. 16, 2013

Dec. 31, 2012

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Note 11 - Subsequent Events (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)

'

'

'

'

'

'

0.5

0.6

'

'

0.6

0.75

0.75

Class of Warrant or Right, Exercises

'

'

-2,933,333

0

'

'

1,166,666

1,766,667

'

1,766,667

'

'

'

Proceeds from Warrant Exercises (in Dollars)

'

'

'

'

'

'

$583,333

$1,060,000

$583,333

$1,060,000

'

'

'

Class of Warrant or Right, Number of Remaining Shares Whose Expiration Was Extended

'

'

'

'

'

'

'

1,166,667

'

'

'

'

'

Other General and Administrative Expense (in Dollars)

$19,617

$218,551

$238,169

'

$152,126

$390,295

'

'

'

$218,551

'

'

'

Schedule_II_Valuation_and_Qual1

Schedule II - Valuation and Qualifying Accounts (Details) - Valuation and Qualifying Accounts (Valuation Allowance of Deferred Tax Assets [Member], USD $)	12 Months Ended
	Dec. 31, 2012		Dec. 31, 2011		Dec. 31, 2010
Valuation Allowance of Deferred Tax Assets [Member]	'		'		'
Valuation Allowance [Line Items]	'		'		'
Balance at Beginning Of Period	$27,591,230		$27,576,253		$27,091,338
Charged to Costs and Expenses	796,237		888,561		1,160,405
Deductions	-1,112,961	[1]	-873,584	[1]	-675,490	[1]
Balance at End Of Period	$27,274,506		$27,591,230		$27,576,253
[1]	Deductions represent the effect of expiring NOL carryforwards from prior years.